These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
112 related articles for article (PubMed ID: 26706116)
1. Design, synthesis and activity evaluation of novel peptide fusion inhibitors targeting HIV-1 gp41. Tan J; Su M; Zeng Y; Wang C Bioorg Med Chem; 2016 Jan; 24(2):201-6. PubMed ID: 26706116 [TBL] [Abstract][Full Text] [Related]
3. Artificial peptides conjugated with cholesterol and pocket-specific small molecules potently inhibit infection by laboratory-adapted and primary HIV-1 isolates and enfuvirtide-resistant HIV-1 strains. Wang C; Shi W; Cai L; Lu L; Yu F; Wang Q; Jiang X; Xu X; Wang K; Xu L; Jiang S; Liu K J Antimicrob Chemother; 2014 Jun; 69(6):1537-45. PubMed ID: 24500189 [TBL] [Abstract][Full Text] [Related]
4. Design of a peptide inhibitor that blocks the cell fusion mediated by glycoprotein 41 of human immunodeficiency virus type 1. Jin BS; Ryu JR; Ahn K; Yu YG AIDS Res Hum Retroviruses; 2000 Nov; 16(17):1797-804. PubMed ID: 11118065 [TBL] [Abstract][Full Text] [Related]
5. Hydrophobic mutations in buried polar residues enhance HIV-1 gp41 N-terminal heptad repeat-C-terminal heptad repeat interactions and C-peptides' anti-HIV activity. Zheng B; Wang K; Lu L; Yu F; Cheng M; Jiang S; Liu K; Cai L AIDS; 2014 Jun; 28(9):1251-60. PubMed ID: 24625369 [TBL] [Abstract][Full Text] [Related]
6. Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection. Wild CT; Shugars DC; Greenwell TK; McDanal CB; Matthews TJ Proc Natl Acad Sci U S A; 1994 Oct; 91(21):9770-4. PubMed ID: 7937889 [TBL] [Abstract][Full Text] [Related]
7. A novel peptide shows excellent anti-HIV-1 potency as a gp41 fusion inhibitor. Liu W; An X; Wang J; Zhang X; Tan J; Zhou Z; Zeng Y Bioorg Med Chem Lett; 2018 Mar; 28(5):910-914. PubMed ID: 29433929 [TBL] [Abstract][Full Text] [Related]
8. A novel HIV-1 gp41 tripartite model for rational design of HIV-1 fusion inhibitors with improved antiviral activity. Su S; Wang Q; Xu W; Yu F; Hua C; Zhu Y; Jiang S; Lu L AIDS; 2017 Apr; 31(7):885-894. PubMed ID: 28121713 [TBL] [Abstract][Full Text] [Related]
9. Protein design of a bacterially expressed HIV-1 gp41 fusion inhibitor. Deng Y; Zheng Q; Ketas TJ; Moore JP; Lu M Biochemistry; 2007 Apr; 46(14):4360-9. PubMed ID: 17371053 [TBL] [Abstract][Full Text] [Related]
10. Supercoiling Structure-Based Design of a Trimeric Coiled-Coil Peptide with High Potency against HIV-1 and Human β-Coronavirus Infection. Wang C; Xia S; Wang X; Li Y; Wang H; Xiang R; Jiang Q; Lan Q; Liang R; Li Q; Huo S; Lu L; Wang Q; Yu F; Liu K; Jiang S J Med Chem; 2022 Feb; 65(4):2809-2819. PubMed ID: 33929200 [TBL] [Abstract][Full Text] [Related]
11. Development of HIV entry inhibitors targeted to the coiled-coil regions of gp41. Jiang S; Debnath AK Biochem Biophys Res Commun; 2000 Mar; 269(3):641-6. PubMed ID: 10720469 [TBL] [Abstract][Full Text] [Related]
12. A salt bridge between an N-terminal coiled coil of gp41 and an antiviral agent targeted to the gp41 core is important for anti-HIV-1 activity. Jiang S; Debnath AK Biochem Biophys Res Commun; 2000 Apr; 270(1):153-7. PubMed ID: 10733920 [TBL] [Abstract][Full Text] [Related]
13. Membrane fusion induced by the HIV type 1 fusion peptide: modulation by factors affecting glycoprotein 41 activity and potential anti-HIV compounds. Pereira FB; Goñi FM; Nieva JL AIDS Res Hum Retroviruses; 1997 Sep; 13(14):1203-11. PubMed ID: 9310287 [TBL] [Abstract][Full Text] [Related]
15. Conjugation of a nonspecific antiviral sapogenin with a specific HIV fusion inhibitor: a promising strategy for discovering new antiviral therapeutics. Wang C; Lu L; Na H; Li X; Wang Q; Jiang X; Xu X; Yu F; Zhang T; Li J; Zhang Z; Zheng B; Liang G; Cai L; Jiang S; Liu K J Med Chem; 2014 Sep; 57(17):7342-54. PubMed ID: 25156906 [TBL] [Abstract][Full Text] [Related]
16. Design, synthesis, and biological evaluation of highly potent small molecule-peptide conjugates as new HIV-1 fusion inhibitors. Wang C; Shi W; Cai L; Lu L; Wang Q; Zhang T; Li J; Zhang Z; Wang K; Xu L; Jiang X; Jiang S; Liu K J Med Chem; 2013 Mar; 56(6):2527-39. PubMed ID: 23458727 [TBL] [Abstract][Full Text] [Related]
17. A novel enzyme-linked immunosorbent assay for screening HIV-1 fusion inhibitors targeting HIV-1 Gp41 core structure. Pang W; Wang RR; Gao YD; Yang LM; Sun Y; Huang JF; Tien P; Zheng YT J Biomol Screen; 2011 Feb; 16(2):221-9. PubMed ID: 21297108 [TBL] [Abstract][Full Text] [Related]
18. Design of a highly potent HIV-1 fusion inhibitor targeting the gp41 pocket. Chong H; Qiu Z; Su Y; Yang L; He Y AIDS; 2015 Jan; 29(1):13-21. PubMed ID: 25562490 [TBL] [Abstract][Full Text] [Related]
19. The amino-terminal peptide of HIV-1 gp41 interacts with human serum albumin. Gordon LM; Curtain CC; McCloyn V; Kirkpatrick A; Mobley PW; Waring AJ AIDS Res Hum Retroviruses; 1993 Nov; 9(11):1145-56. PubMed ID: 8312056 [TBL] [Abstract][Full Text] [Related]
20. Antivirals that target the amino-terminal domain of HIV type 1 glycoprotein 41. Gordon LM; Waring AJ; Curtain CC; Kirkpatrick A; Leung C; Faull K; Mobley PW AIDS Res Hum Retroviruses; 1995 Jun; 11(6):677-86. PubMed ID: 7576927 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]